Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
..."This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It also provided superior tumor control and resulted in dramatically improved survival rates in a mouse model of colorectal cancer.
Chief Scientific Officer, Agnete Fredriksen, commented on the findings, "Our latest data not only emphasize the effectiveness of the APC-targeted approach but also confirm our platform's potential across modalities to significantly advance the treatment landscape for cancer. The strong data demonstrating Nykode’s potential to improve mRNA vaccines underscore our commitment to leading the way in next-generation immunotherapies.""...
https://newsweb.oslobors.no/message/621130
Chief Scientific Officer, Agnete Fredriksen, commented on the findings, "Our latest data not only emphasize the effectiveness of the APC-targeted approach but also confirm our platform's potential across modalities to significantly advance the treatment landscape for cancer. The strong data demonstrating Nykode’s potential to improve mRNA vaccines underscore our commitment to leading the way in next-generation immunotherapies.""...
https://newsweb.oslobors.no/message/621130
DrDental
I dag kl 10:23
206
Skyter fart nå. I et 5-års perspektiv er denne helt klart en mangedoblingskandidat.
DrDental
26.06.2024 kl 13:40
816
Når Martin Mølsæter anbefaler kjøp - bør man lystre. Denne har et enormt potensiale. På disse nivåene er det bare å laste opp.
omvo
12.06.2024 kl 08:46
1242
Gårdagens fra ABG:
Nykode Therapeutics, NYKD NO: BUY, TP NOK 80.0
Healthcare, MCap EURm 467, SP NOK 16.40
New preclinical data on mRNA neoantigen vaccibody
mRNA-neoantigen vaccibody superior to untargeted mRNA vaccine
Broader T cell response translates into...
...improved tumour control/survival in a CRC mouse model.
New mRNA-VB data presented in Boston
Today Nykode announced the presentation of preclinical data from its mRNA-lipid nanoparticle (LNP) platform, presented yesterday at the Cancer immunotherapy meeting in Boston. As a reminder, the mRNA vaccibody (VB) has the same design principle as a "classic" DNA vaccibody, however it is encoded as mRNA and packaged into LNPs. The dataset presented builds up on data presented last October at the mRNA Cancer Vaccines Summit 2023 (our note).
Broader T cell response and improved tumour control
In the study, Nykode used a vaccine design based on neoantigens from the colorectal (CRC) MC38 tumour model. The vaccibody was compared to mRNA encoding only the untargeted antigen (i.e. without the targeting and dimerization domain; "antigen"). Firstly, the vaccibody showed a substantially stronger T cell response vs. the untargeted antigen after only one vaccination. The magnitude of this difference between the two exp. groups shrank after a 2nd "boost" vaccination. However, still the vaccibody showed a broader T cell response towards more (+6) neoantigens vs. the untargeted mRNA vaccine. Interestingly, the additional neoantigens showed a relatively weak response (as measured by FluoroSpot IFNg SFU assay), compared to the shared/common neoantigen responses elicited by both vaccines. Most importantly though, this seemingly small difference of the ex vivo T cell response translated into a substantial effect in vivo in the mouse MC38 colorectal tumour model, showing a shrinking tumour volume and improved survival vs. the untargeted antigen vaccine and the control group. We note that we do not know the experimental details of the initial T cell response experiments, but we note that T cell responses in vivo often take several weeks to amplify and mature with the tumour cells triggering the responses in vivo. We speculate that the follow-up time in the FluoroSpot experiments could have been too short to see the full magnitude of the additional induced T cell neoantigen response.
mRNA platform could open new doors
We view the data as another positive and important building block adding to Nykode's mRNA platform, expecting a small positive share price reaction. We believe that Nykode is testing different modalities to select the most optimal candidate with the highest promise to proceed with in future development. Notably, several other companies active in the cancer vaccine space work with untargeted mRNA neoantigen vaccines already in the clinic, and for Nykode it could be interesting from a business development perspective to actively engage in this space, showcasing the potential of its vaccibody technology to improve upon classic mRNA neoantigen vaccines. Finally, we note that this dataset could be a preparation for the NYK011 colorectal vaccine programme for which we expect an update in H2'24.
Nykode Therapeutics, NYKD NO: BUY, TP NOK 80.0
Healthcare, MCap EURm 467, SP NOK 16.40
New preclinical data on mRNA neoantigen vaccibody
mRNA-neoantigen vaccibody superior to untargeted mRNA vaccine
Broader T cell response translates into...
...improved tumour control/survival in a CRC mouse model.
New mRNA-VB data presented in Boston
Today Nykode announced the presentation of preclinical data from its mRNA-lipid nanoparticle (LNP) platform, presented yesterday at the Cancer immunotherapy meeting in Boston. As a reminder, the mRNA vaccibody (VB) has the same design principle as a "classic" DNA vaccibody, however it is encoded as mRNA and packaged into LNPs. The dataset presented builds up on data presented last October at the mRNA Cancer Vaccines Summit 2023 (our note).
Broader T cell response and improved tumour control
In the study, Nykode used a vaccine design based on neoantigens from the colorectal (CRC) MC38 tumour model. The vaccibody was compared to mRNA encoding only the untargeted antigen (i.e. without the targeting and dimerization domain; "antigen"). Firstly, the vaccibody showed a substantially stronger T cell response vs. the untargeted antigen after only one vaccination. The magnitude of this difference between the two exp. groups shrank after a 2nd "boost" vaccination. However, still the vaccibody showed a broader T cell response towards more (+6) neoantigens vs. the untargeted mRNA vaccine. Interestingly, the additional neoantigens showed a relatively weak response (as measured by FluoroSpot IFNg SFU assay), compared to the shared/common neoantigen responses elicited by both vaccines. Most importantly though, this seemingly small difference of the ex vivo T cell response translated into a substantial effect in vivo in the mouse MC38 colorectal tumour model, showing a shrinking tumour volume and improved survival vs. the untargeted antigen vaccine and the control group. We note that we do not know the experimental details of the initial T cell response experiments, but we note that T cell responses in vivo often take several weeks to amplify and mature with the tumour cells triggering the responses in vivo. We speculate that the follow-up time in the FluoroSpot experiments could have been too short to see the full magnitude of the additional induced T cell neoantigen response.
mRNA platform could open new doors
We view the data as another positive and important building block adding to Nykode's mRNA platform, expecting a small positive share price reaction. We believe that Nykode is testing different modalities to select the most optimal candidate with the highest promise to proceed with in future development. Notably, several other companies active in the cancer vaccine space work with untargeted mRNA neoantigen vaccines already in the clinic, and for Nykode it could be interesting from a business development perspective to actively engage in this space, showcasing the potential of its vaccibody technology to improve upon classic mRNA neoantigen vaccines. Finally, we note that this dataset could be a preparation for the NYK011 colorectal vaccine programme for which we expect an update in H2'24.